@article{f3f63d7558f642eeb873c5a8d1f6ef1f,
title = "Modified dose of guselkumab for treatment of pyoderma gangrenosum",
keywords = "biologics (Rx), clinical cases, immunobiologics, leg ulcers, medical dermatology, pyoderma gangrenosum, ulcers, wounds & wound healing",
author = "Reese, {Ashley M.} and Katherine Erickson and Reed, {Katherine B.} and Ortega-Loayza, {Alex G.}",
note = "Funding Information: Dr Ortega-Loayza has served in advisory boards for Janssen, BMS, and Boehringer Ingelheim and as a consultant for Genentech and Guidepoint. He has also received research grants from Eli Lilly Company , Oregon Health & Science University School of Medicine Gerlinger research award, and Medical Research Foundation of Oregon . Author Reese and Drs Erickson and Reed have no conflicts of interest to declare. Funding Information: Dr Ortega-Loayza has served in advisory boards for Janssen, BMS, and Boehringer Ingelheim and as a consultant for Genentech and Guidepoint. He has also received research grants from Eli Lilly Company, Oregon Health & Science University School of Medicine Gerlinger research award, and Medical Research Foundation of Oregon. Author Reese and Drs Erickson and Reed have no conflicts of interest to declare. Funding sources: None.",
year = "2022",
month = mar,
doi = "10.1016/j.jdcr.2021.11.030",
language = "English (US)",
volume = "21",
pages = "38--42",
journal = "JAAD Case Reports",
issn = "2352-5126",
publisher = "Elsevier Inc.",
}